Registration at the Danish Business Authority

As previously announced by FluoGuide A/S (“FluoGuide” or “the Company”), the guarantors who through a compensation free guarantee guaranteed up to approximately 19% of the warrants of series TO 1 exercise were allocated 27,737 shares, corresponding to approximately 2.4 % of the maximum warrant exercise volume. The registration of the 27,737 shares is for technical reasons done as not-exercised warrants instead of as a directed issue, which means that the existing authorization to the Board of Directors given at the Annual General Meeting to issue shares will not be utilized for the allocation of the 27,737 shares for the grantors. 

Number of shares and share capital
 The change of registration procedure for the 27,737 shares does not change the total number of shares or the proceeds for the Company, compared to what has already been announced. When the new shares have been registered with the Danish Business Authority (in Danish “Erhvervsstyrelsen”), the total number of shares in FluoGuide will amount to 10,530,026 shares and the share capital will amount to DKK 1,053,002.60. 

Financial advisor and legal advisor
Sedermera Fondkommission has acted as financial advisor in the warrant exercise and the directed issue. Markets & Corporate Law Nordic AB has acted as legal advisor.

For further information regarding the warrants of series TO 1 and the directed issue, please contact:
Sedermera Fondkommission
+46 40 615 14 10
info@sedermera.se
www.sedermera.se

For further information, please contact:
Morten Albrechtsen, CEO
M: +45 24 25 62 66
ma@fluoguide.com

About FluoGuide
FluoGuide’s primary focus is to maximize surgical outcomes in oncology. The Company’s first product, FG001, is designed to improve surgical precision by illuminating cancer cells intraoperatively. The improved precision enabled by FluoGuide’s products has a dual benefit – it reduces both the frequency of local recurrence post-surgery and lessens surgical sequelae. Ultimately, these improvements will improve a patient’s chance of achieving a complete cure and will lower system-wide healthcare costs. The Company is planning a proof-of-concept clinical study (phase I/IIa) to demonstrate the effect of FG001 in patients with glioblastoma.